These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27230052)

  • 1. Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes.
    Asleh R; Levy NS; Doros G; Costacou T; Robinson JG; Blum S; Goldenstein H; Boden WE; Simmons DL; Lacy MA; Grunberger G; Anderson TJ; Levy AP
    J Am Coll Cardiol; 2016 May; 67(21):2553-4. PubMed ID: 27230052
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype.
    Farbstein D; Blum S; Pollak M; Asaf R; Viener HL; Lache O; Asleh R; Miller-Lotan R; Barkay I; Star M; Schwartz A; Kalet-Littman S; Ozeri D; Vaya J; Tavori H; Vardi M; Laor A; Bucher SE; Anbinder Y; Moskovich D; Abbas N; Perry N; Levy Y; Levy AP
    Atherosclerosis; 2011 Nov; 219(1):240-4. PubMed ID: 21722898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haptoglobin Genotype Is a Determinant of Hemoglobin Adducts and Vitamin E Content in HDL.
    Goldenstein H; Levy NS; Ward J; Costacou T; Levy AP
    J Diabetes Res; 2018; 2018():6125420. PubMed ID: 29888289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy and clinical trials.
    Elmallah W; Krasuski RA
    Curr Opin Lipidol; 2011 Dec; 22(6):512-3. PubMed ID: 22101564
    [No Abstract]   [Full Text] [Related]  

  • 5. High-density lipoprotein particles, coronary heart disease, and niacin.
    Asztalos BF
    J Clin Lipidol; 2010; 4(5):405-10. PubMed ID: 21122684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype.
    Asleh R; Levy AP
    Antioxid Redox Signal; 2010 Feb; 12(2):209-17. PubMed ID: 19769483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niacin: old habits die hard.
    Haynes R; Rahimi K
    Heart; 2016 Feb; 102(3):170-1. PubMed ID: 26769376
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
    Pan J; Shilian P; Ishida B; Wu X; Kane JP; Malloy MJ; Charles MA
    Metabolism; 2011 Feb; 60(2):292-7. PubMed ID: 20303127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease.
    Blum S; Milman U; Shapira C; Levy AP
    Pharmacogenomics; 2008 Aug; 9(8):989-91. PubMed ID: 18681772
    [No Abstract]   [Full Text] [Related]  

  • 11. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New thinking on niacin use. Using niacin to raise "good" cholesterol doesn't lower your risk of having a heart attack or stroke.
    Harv Health Lett; 2014 Aug; 39(10):6. PubMed ID: 25230410
    [No Abstract]   [Full Text] [Related]  

  • 13. Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.
    Harv Health Lett; 2007 Apr; 32(6):6. PubMed ID: 17390509
    [No Abstract]   [Full Text] [Related]  

  • 14. Niacin: Time to Believe Outcomes Over Surrogate Outcomes: If Not Now, When?
    Krumholz HM
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):343-4. PubMed ID: 27407051
    [No Abstract]   [Full Text] [Related]  

  • 15. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
    Tai ES; Collins D; Robins SJ; O'Connor JJ; Bloomfield HE; Ordovas JM; Schaefer EJ; Brousseau ME
    Atherosclerosis; 2006 Jul; 187(1):153-60. PubMed ID: 16221474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haptoglobin: basic and clinical aspects.
    Levy AP; Asleh R; Blum S; Levy NS; Miller-Lotan R; Kalet-Litman S; Anbinder Y; Lache O; Nakhoul FM; Asaf R; Farbstein D; Pollak M; Soloveichik YZ; Strauss M; Alshiek J; Livshits A; Schwartz A; Awad H; Jad K; Goldenstein H
    Antioxid Redox Signal; 2010 Feb; 12(2):293-304. PubMed ID: 19659435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2.
    Taylor AJ; Zhu D; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Vasc Health Risk Manag; 2007; 3(1):159-64. PubMed ID: 17583186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes.
    Somer S; Levy AP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The surprising AIM-HIGH results are not surprising when viewed through a particle lens.
    Otvos JD
    J Clin Lipidol; 2011; 5(5):368-70. PubMed ID: 21981836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.